These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12042846)

  • 21. Biotech bonanza.
    Stipp D
    Fortune; 1999 Nov; 140(9):333-4. PubMed ID: 10623111
    [No Abstract]   [Full Text] [Related]  

  • 22. Trends in biopharmaceutical IPOS: 1996-2005.
    Williams DR; Young CC
    J Health Care Finance; 2006; 33(2):39-54. PubMed ID: 19175239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HGS drug flop latest genomics setback.
    Reid B
    Nat Biotechnol; 2002 Jun; 20(6):533. PubMed ID: 12042841
    [No Abstract]   [Full Text] [Related]  

  • 24. Silent running: the race to the clinic.
    Nature; 2006 Aug; 442(7103):614-5. PubMed ID: 16900171
    [No Abstract]   [Full Text] [Related]  

  • 25. As Genzyme flounders, competitors and activist investors swoop in.
    Allison M
    Nat Biotechnol; 2010 Jan; 28(1):3-4. PubMed ID: 20062016
    [No Abstract]   [Full Text] [Related]  

  • 26. How Genentech got it.
    Stipp D
    Fortune; 2003 Jun; 147(11):81-2, 84, 86 passim. PubMed ID: 12800575
    [No Abstract]   [Full Text] [Related]  

  • 27. Nasdaq restructures biotech index.
    Morrison C
    Nat Biotechnol; 2001 Mar; 19(3):187. PubMed ID: 11231518
    [No Abstract]   [Full Text] [Related]  

  • 28. Can personalized drugs pay off?
    Stipp D
    Fortune; 2002 May; 145(10):168. PubMed ID: 12025349
    [No Abstract]   [Full Text] [Related]  

  • 29. When a long shot is worth a shot.
    Jacobs T; Fischer J
    Nat Biotechnol; 2005 Jul; 23(7):805. PubMed ID: 16003361
    [No Abstract]   [Full Text] [Related]  

  • 30. Spinning the wheel on ImClone.
    Varchaver N
    Fortune; 2003 Apr; 147(8):123-5. PubMed ID: 12728651
    [No Abstract]   [Full Text] [Related]  

  • 31. Investors likely to venture back as crisis subsides.
    Glick JL
    Nature; 2009 Aug; 460(7259):1079. PubMed ID: 19713912
    [No Abstract]   [Full Text] [Related]  

  • 32. Biotechnology in the Medicon Valley.
    Frank L
    Nature; 2002 Dec; 420(6916 Suppl):A27, A29, A31 passim. PubMed ID: 12501124
    [No Abstract]   [Full Text] [Related]  

  • 33. How the street sees biotech.
    Lashinsky A
    Fortune; 2003 Jun; 147(11):86. PubMed ID: 12800576
    [No Abstract]   [Full Text] [Related]  

  • 34. Biotech slumps in Q1.
    Lawrence S
    Nat Biotechnol; 2008 May; 26(5):486. PubMed ID: 18464769
    [No Abstract]   [Full Text] [Related]  

  • 35. Fresh horizons South Korea.
    Cyranoski D
    Nature; 2002 Dec; 420(6916):4-5. PubMed ID: 12478244
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmas partner in venture seeking drug discovery tools.
    Mack GS
    Nat Biotechnol; 2008 Sep; 26(9):960-1. PubMed ID: 18779790
    [No Abstract]   [Full Text] [Related]  

  • 37. New pharma-biotech company formation in India.
    Saberwal G
    Nat Biotechnol; 2006 May; 24(5):499-501. PubMed ID: 16680124
    [No Abstract]   [Full Text] [Related]  

  • 38. A special biotech speculation.
    Jacobs T
    Nat Biotechnol; 2006 Jun; 24(6):622. PubMed ID: 16763586
    [No Abstract]   [Full Text] [Related]  

  • 39. A new prescription for your portfolio.
    Clifford L; O'Keefe B; Stires D
    Fortune; 2001 Jul; 144(2):74-6, 78, 80. PubMed ID: 11471357
    [No Abstract]   [Full Text] [Related]  

  • 40. Maturing biotechs turn to pharma's markets.
    Ratner M
    Nat Biotechnol; 2005 Mar; 23(3):269. PubMed ID: 15765067
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.